At the news
? MIXEDIMPACT 6/10 8-K filed Mar 5, 2026 at 16:11 ET
Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with completion of the PH-762 Phase 1b trial, $23.7 million in net proceeds from financings and warrant exercises, and an extended cash runway into the first half of 2027. The company reported a net loss of $8.7 million for 2025, up from $7.2 million in 2024, due to increased R&D and G&A spending.
- Completed Phase 1b dose-escalation trial for lead candidate PH-762 with favorable safety and tolerability data
- Raised $23.7 million in net proceeds during 2025 through equity financings and warrant exercises
- Cash position increased to $21.0 million at year-end 2025 from $5.4 million at year-end 2024
- Cash runway extended into the first half of 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access